🇺🇸 FDA
Pipeline program

APVO436

APVO436-5201

Phase 1 small_molecule active

Quick answer

APVO436 for Acute Myeloid Leukemia (AML) is a Phase 1 program (small_molecule) at Aptevo Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Aptevo Therapeutics
Indication
Acute Myeloid Leukemia (AML)
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials